RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cardiovascular Research

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CARDIORES.2006.01.026PMID 16545351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Mechanism of Atrial Antiarrhythmic Action of RSD1235

  2005influential reference
• Oral class III antiarrhythmics: what is new?

  2004cited by this paper
• A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.

  2004cited by this paper
• Role of individual ionic current systems in ventricular cells hypothesized by a model study.

  2003cited by this paper
• Drug induced QT prolongation and torsades de pointes

  2003cited by this paper
• Non-Equilibrium Gating in Cardiac Na+ Channels: An Original Mechanism of Arrhythmia

  2003cited by this paper
• Midterm Results After Stentless Mitral Valve Replacement

  2003cited by this paper
• Genetic basis for the origin of cardiac arrhythmias: Implications for therapy

  2002cited by this paper
• Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes

  2002influential reference
• Cytosolic Ca2+ triggers early afterdepolarizations and torsade de pointes in rabbit hearts with type 2 long QT syndrome

  2002cited by this paper
• Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potential.

  2001cited by this paper
• Species Plays an Important Role in Drug‐Induced Prolongation of Action Potential Duration and Early Afterdepolarizations in Isolated Purkinje Fibers

  2001cited by this paper
• Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts.

  2000cited by this paper
• Selective block of late Na+ current by local anaesthetics in rat large sensory neurones

  2000cited by this paper
• Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.

  2000cited by this paper
• Long QT Syndrome:

  2000cited by this paper
• Electrical heterogeneity, cardiac arrhythmias, and the sodium channel.

  2000cited by this paper
• Preferential Block of Late Sodium Current in the LQT3 ΔKPQ Mutant by the Class IC Antiarrhythmic Flecainide

  2000cited by this paper
• Enhancement of delayed afterdepolarizations and triggered activity by class III antiarrhythmic drugs: multiple effects of E-4031 and dofetilide.

  2000cited by this paper
• Current Antiarrhythmic Drugs

  1999cited by this paper
• Ion channels and ventricular arrhythmias: cellular and ionic mechanisms underlying the Brugada syndrome.

  1999cited by this paper
• The M Cell:

  1999cited by this paper
• Mechanisms of atrial fibrillation and action of drugs used in its management.

  1998cited by this paper
• Effects of Sodium Channel Block with Mexiletine to Reverse Action Potential Prolongation in In Vitro Models of the Long QT Syndrome

  1997cited by this paper
• Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.

  1996cited by this paper
• Lidocaine and Nisoldipine Attenuate Almokalant‐Induced Dispersion of Repolarization and Early Afterdepolarizations In Vitro

  1996cited by this paper
• Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

  1996cited by this paper
• Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031.

  1993cited by this paper
• QTU‐Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit: Etiology and Interventions

  1990cited by this paper
• Ventricular fibrillation and torsades de pointes

  1990cited by this paper
• Early Afterdepolarizations: Mechanism of Induction and Block A Role for L‐Type Ca2+ Current

  1989cited by this paper
• Cardiovascular Research

  1966cited by this paper
• [Ventricular tachycardia with 2 variable opposing foci].

  1966cited by this paper

• Tic-Tac: A Translational Approach in Mechanisms Associated with Irregular Heartbeat and Sinus Rhythm Restoration in Atrial Fibrillation Patients

  2023cites this paper
• Bifurcations to transient and oscillatory excitations in inhomogeneous excitable media: Insights into arrhythmogenesis in long QT syndrome.

  2023cites this paper
• Fibroblast Growth Factor 1 Reduces Pulmonary Vein and Atrium Arrhythmogenesis via Modification of Oxidative Stress and Sodium/Calcium Homeostasis

  2022cites this paper
• QT Dispersion and Drug-Induced Torsade de Pointes

  2021cites this paper
• Testing the limits of cardiac electrophysiology models through systematic variation of current

  2020cites this paper
• Cardiac Mechano-Electric Coupling: Acute Effects of Mechanical Stimulation on Heart Rate and Rhythm.

  2020cites this paper
• Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

  2020cites this paper
• Dynamics of propagation patterns and anti-arrhythmic mechanisms during atrial fibrillation

  2019cites this paper
• Cardiovascular Safety Pharmacology Issue Resolution

  2019cites this paper
• Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

  2018cites this paper
• Study the Effects of Vernakalant on Ischemic-Reperfusion Dysrhythmias in Experimental Animals in Comparison with Amiodarone

  2018cites this paper
• Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels

  2018cites this paper
• Antiarrhythmic effect of vernakalant in an experimental model of Long-QT-syndrome

  2017cites this paper
• Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation

  2017influential citation
• Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re‐evaluation of an established drug

  2017cites this paper
• Sodium channel biophysics, late sodium current and genetic arrhythmic syndromes

  2017cites this paper
• Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment

  2017cites this paper
• Tolterodine reduces veratridine-augmented late INa, reverse-INCX and early afterdepolarizations in isolated rabbit ventricular myocytes

  2016cites this paper
• Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.

  2016cites this paper
• Suppression of Early and Late Afterdepolarizations by Heterozygous Knockout of the Na+/Ca2+ Exchanger in a Murine Model

  2015cites this paper
• Complex Early and Delayed Afterdepolarization Dynamics caused by Voltage-Calcium Coupling in Cardiac Myocytes

  2015cites this paper
• Vernakalant en la reversión de la fibrilación auricular de reciente comienzo

  2015cites this paper
• Ranolazine for the treatment of atrial fibrillation

  2015cites this paper
• Preventing Recurrences: Classic and Modern Antiarrhythmic Drugs in Atrial

  2015cites this paper
• [Vernakalant for the conversion of atrial fibrillation of recent onset].

  2015cites this paper
• Calcium-voltage coupling in the genesis of early and delayed afterdepolarizations in cardiac myocytes.

  2015cites this paper
• Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation.

  2014cites this paper
• Comparison between Carotid Artery Doppler Ultrasound and Coronary Calcium Score as Predictors of Significant Coronary Artery Disease in Patients Undergoing Computed Tomography Coronary Angiography

  2014cites this paper
• Atrial Fibrillation Therapy Now and in the Future: Drugs, Biologicals, and Ablation

  2014cites this paper
• Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization.

  2014influential citation
• Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.

  2014cites this paper
• Future perspectives in the pharmacological treatment of atrial fibrillation and ventricular arrhythmias in heart failure.

  2014cites this paper
• The role of late I Na in development of cardiac arrhythmias.

  2014influential citation
• [New developments in the antiarrhythmic therapy of atrial fibrillation].

  2014cites this paper
• Neue Entwicklungen in der antiarrhythmischen Therapie des Vorhofflimmerns

  2014cites this paper
• 112 – New Antiarrhythmic Drugs and New Concepts for Old Drugs

  2014cites this paper
• Vernakalant hydrochloride to treat atrial fibrillation

  2014cites this paper
• Vernakalant for the Conversion of Atrial Fibrillation: The New Kid On the Block?

  2014cites this paper
• Cellular Pharmacology of Cardiac Automaticity and Conduction: Implications in Antiarrhythmic Drug Assessment

  2014cites this paper
• An emerging antiarrhythmic target: late sodium current.

  2014cites this paper
• Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.

  2014cites this paper
• Non-surgical Treatment and Prevention of Atrial Fibrillation

  2013cites this paper
• Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model.

  2013cites this paper
• The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.

  2013cites this paper
• The arrhythmogenic consequences of increasing late INa in the cardiomyocyte.

  2013cites this paper
• Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models

  2013cites this paper
• Simulation of early after-depolarisation in non-failing human ventricular myocytes: Can this help cardiac safety pharmacology?

  2013cites this paper
• Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update

  2013cites this paper
• Acquired (Drug-Induced) Long and Short QT Syndromes

  2013cites this paper
• Efficacy and Safety of Vernakalant in Recent‐Onset Atrial Fibrillation After the European Medicines Agency Approval: Systematic Review and Meta‐Analysis

  2012cites this paper
• Mechano-sensitivity of cardiac pacemaker function: Pathophysiological relevance, experimental implications, and conceptual integration with other mechanisms of rhythmicity

  2012cites this paper
• Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation

  2012cites this paper
• Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity

  2012cites this paper
• Vernakalant: Review of a Novel Atrial Selective Antiarrhythmic Agent and its Place in Current Treatment of Atrial Fibrillation

  2012cites this paper
• Novel Approaches for Pharmacological Management of Atrial Fibrillation

  2012cites this paper
• Atrial Fibrillation Antiarrhythmic Drug Therapy for Atrial Fibrillation

  2012cites this paper
• Cardiac ion channels and mechanisms for protection against atrial fibrillation.

  2012cites this paper
• Antiarrhythmic drug therapy for atrial fibrillation.

  2012cites this paper
• Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation.

  2012cites this paper
• Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel: Comparison With Ranolazine and dl-Sotalol

  2012influential citation
• Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence

  2011cites this paper
• Ion channels and their inhibitors

  2011cites this paper
• Potassium Channel Blockers as Antiarrhythmic Agents

  2011cites this paper
• A Model of Canine Purkinje Cell Electrophysiology and Ca2+ Cycling: Rate Dependence, Triggered Activity, and Comparison to Ventricular Myocytes

  2011cites this paper
• Atrial Selective Effects of Intravenously Administered Vernakalant in Conscious Beagle Dogs

  2011cites this paper
• The pharmaceutical pipeline for atrial fibrillation

  2011cites this paper
• Advances in Design and Development of Sodium Channel Blockers

  2011cites this paper
• Vernakalant Selectively Prolongs Atrial Refractoriness With No Effect on Ventricular Refractoriness or Defibrillation Threshold in Pigs

  2011cites this paper
• Spotlight on Intravenous Vernakalant in Recent-Onset Atrial Fibrillation

  2011cites this paper
• Vernakalant: A New Drug to Treat Patients With Acute Onset Atrial Fibrillation

  2011cites this paper
• Supplemental Studies for Cardiovascular Risk Assessment in Safety Pharmacology: A Critical Overview

  2011cites this paper
• Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.

  2011cites this paper
• Antiarrhythmic drugs for atrial fibrillation

  2011cites this paper
• Intravenous Vernakalant

  2011cites this paper
• Population pharmacokinetic–pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter

  2011cites this paper
• Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.

  2010cites this paper
• New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation.

  2010cites this paper
• Effects of late sodium current enhancement during LQT-related arrhythmias. A simulation study

  2010cites this paper
• Role of the late sodium current in arrhythmias related to low repolarization reserve

  2010cites this paper
• Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy

  2010cites this paper
• The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability.

  2010cites this paper
• Structure‐Based Virtual Screening and Electrophysiological Evaluation of New Chemotypes of Kv1.5 Channel Blockers

  2010cites this paper
• Augmenting Maintenance of Sinus Rhythm in the Control of Atrial Fibrillation by Antiarrhythmic Drug Combinations

  2010cites this paper
• Vernakalant (Kynapid): An Investigational Drug for the Treatment of Atrial Fibrillation

  2010cites this paper
• La ranolazina en el tratamiento de las arritmias

  2010cites this paper
• Ranolazina: ¿tratamiento potencial de las arritmias?

  2010cites this paper
• Antiarrhythmic therapy in atrial fibrillation.

  2010cites this paper
• Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In Vivo

  2009cites this paper
• Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential.

  2009cites this paper
• Atrial fibrillation: from ion channels to bedside treatment options.

  2009cites this paper
• Potentiation of dofetilide LQT-related effects by late sodium current enhancement: A simulation study

  2009cites this paper
• Cardioversion for Atrial Fibrillation: Treatment Options and Advances

  2009cites this paper
• Pharmacotherapy Options in Atrial Fibrillation: Focus on Vernakalant

  2009cites this paper
• I Kur /Kv1.5channelblockersforthe treatmentofatrialfibrillation

  2009cites this paper
• Advances in Arrhythmia and Electrophysiology New Pharmacological Agents for Arrhythmias

  2009cites this paper
• Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts.

  2009cites this paper
• Persistent (current) in the face of adversity … A new class of cardiac anti‐ischaemic compounds on the horizon?

  2009cites this paper
• The Emerging Role of Antiarrhythmic Compounds With Atrial Selectivity in the Management of Atrial Fibrillation

  2009cites this paper
• Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.

  2009cites this paper
• I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.

  2009cites this paper